Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee Osteoarthritis
R3 Medical Research · NCT06608134
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 30+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Early Phase 1
- Target enrollment
- 120
- US sites recruiting
- 5
- Study start
- October 1, 2024
- Record last updated
- September 23, 2024
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is a Pilot Study which is randomized, prospective, open label, dose escalation, non-controlled evaluating safety and feasibility of intra-articular Wharton's Jelly (WJ) allograft will be evaluated in patients suffering with knee osteoarthritis. The participants will be randomized to one of three dosing treatment arms that will consist of one intra-articular knee injection containing either low dose, medium dose or high dose WJ allograft tissue.
Being studied: Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee Injection
Conditions: Osteoarthritis, Knee
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Be over age 30
- Diagnosed with Grade II or III OA on the KL scale (in one knee).
- Body Mass Index (BMI) \<50Kg/m2
- Pain score of 4 or more on the Numeric Pain Rating Scale (NPRS)
- Female patients must be abstinent, surgically sterilized or postmenopausal
- Premenopausal females must have a negative pregnancy test, on contraceptive measures and do not anticipate pregnancy during the duration of the study.
- Be willing and capable of giving written informed consent to participate in English.
- Be willing and capable of complying with study-related requirements, procedures and visits in English.
Exclusion Criteria
- Have taken any pain medication including nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to study injection date.
- Use anticoagulants have a substance abuse history and fail to agree not to take any knee-symptom modifying drugs during the course of the study without discussing and reporting the use to the site principal investigator and study team.
- Have had an intra-articular injection of any drug including viscosupplementation in the index knee in the past 6 months.
- Have had surgery on the index knee with the past 6 months.
- Had a traumatic injury to the index knee with the past 3 months.
- Planned elective surgery during the course of the study.
- A history of organ or hematologic transplantation, rheumatoid arthritis, or other autoimmune disorders.
- Be on immunosuppressive medications.
- Have a diagnosis of carcinoma with the past 2 years.
- Have a knee infection or have used antibiotics for knee infection within the past 3 months.
- Have participated in any other clinical trial or treatment (not just for the knee, but for any reason) with any investigational product within the past 30 days prior to inclusion of study.
- Female patients who are breast feeding or are pregnant or desire to become pregnant during the course of the study.
- Contraindications to radiographic or MRI imaging.
- Serious neurological, psychological or psychiatric disorders.
- Injury or disability claims under current litigation or pending or approved workers compensation claims.
- Have a known drug allergy to amphotericin-B, ciprofloxacin, gentamycin, penicillin, or streptomycin.
Recruiting US locations
R3 Anti Aging Scottsdale
Scottsdale, AZ 85262
Site contact: Dr. Sabrina Solt, NMD · 480-306-6256 · info@r3medicalresearch.com
R3 Anti Aging Beverly Hills
Beverly Hills, CA 90210
Site contact: Neville Campbell, MD · 424-382-1074 · info@r3medicalresearch.com
Optimal Medical Group
Fresno, CA 93722
Site contact: Dr. Lucia Mireles-Chavez, MD · 559-425-1118 · info@r3medicalresearch.com
Scheer Medical Wellness
New York, NY 10036
Site contact: Dr. Alexandre Scheer, MD · 212-391-8080 · info@r3medicalresearch.com
Dr. Duc (Steve) Le, MD
Cleveland, TX 77327
Site contact: Duc Le, MD · 281-593-1500 · info@r3medicalresearch.com
Similar studies in Arizona
All arthritis studies in Arizona →- RecruitingHealthy volunteersPhase 1
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
Eli Lilly and Company
- Location
- Phoenix, AZ + 8 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
Merck Sharp & Dohme LLC
- Location
- Chandler, AZ + 35 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis
Medipost, Inc.
- Location
- Scottsdale, AZ + 33 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P)
Doron Therapeutics Inc.
- Location
- Tucson, AZ + 7 other US sites
- Eligibility basics
- Ages 40–80